Nishan Garabedian Christopher insider trades: Sarepta Therapeutics (SRPT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nishan reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 27, 2015 | SRPT | ↑ Buy | 800 | $11.81 | $9K | Direct | Mar 3, 2015 (4d) |
| Dec 15, 2011 | AVII | ↑ Buy | 300,000 | $0.58 | $174K | Direct | Dec 16, 2011 (1d) |
| Apr 6, 2011 | AVII | ↑ Buy | 130,000 | $1.50 | $195K | Direct | Apr 6, 2011 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SRPT insiders
Open-market trades in the last 12 months
About Nishan Garabedian Christopher's insider trades
Nishan Garabedian Christopher is President and CEO at Sarepta Therapeutics (SRPT). Since Apr 6, 2011, Nishan has reported 3 open-market purchases worth $378K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SRPT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.